Sinopharm Group Ltd Stock Cash Per Share
| SHTDY Stock | USD 13.31 0.33 2.54% |
SINOPHARM GROUP LTD fundamentals help investors to digest information that contributes to SINOPHARM GROUP's financial success or failures. It also enables traders to predict the movement of SINOPHARM Pink Sheet. The fundamental analysis module provides a way to measure SINOPHARM GROUP's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SINOPHARM GROUP pink sheet.
SINOPHARM |
SINOPHARM GROUP LTD Company Cash Per Share Analysis
SINOPHARM GROUP's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current SINOPHARM GROUP Cash Per Share | 61.23 X |
Most of SINOPHARM GROUP's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SINOPHARM GROUP LTD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, SINOPHARM GROUP LTD has a Cash Per Share of 61 times. This is much higher than that of the Healthcare sector and notably higher than that of the Medical Distribution industry. The cash per share for all United States stocks is notably lower than that of the firm.
SINOPHARM Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SINOPHARM GROUP's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of SINOPHARM GROUP could also be used in its relative valuation, which is a method of valuing SINOPHARM GROUP by comparing valuation metrics of similar companies.SINOPHARM GROUP is currently under evaluation in cash per share category among its peers.
SINOPHARM Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 624.13 M | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 6.27 X | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 521.05 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 20.76 B | |||
| Net Income | 7.76 B | |||
| Cash And Equivalents | 38.21 B | |||
| Cash Per Share | 61.23 X | |||
| Total Debt | 8.42 B | |||
| Debt To Equity | 0.71 % | |||
| Current Ratio | 1.31 X | |||
| Book Value Per Share | 105.05 X | |||
| Cash Flow From Operations | 9.31 B | |||
| Earnings Per Share | 1.86 X | |||
| Price To Earnings To Growth | 50.92 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.72 | |||
| Market Capitalization | 8.61 B | |||
| Total Asset | 335.41 B | |||
| Retained Earnings | 11.43 B | |||
| Working Capital | 32.26 B | |||
| Current Asset | 130.51 B | |||
| Current Liabilities | 98.25 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.15 % | |||
| Net Asset | 335.41 B | |||
| Last Dividend Paid | 0.75 |
About SINOPHARM GROUP Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SINOPHARM GROUP LTD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SINOPHARM GROUP using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SINOPHARM GROUP LTD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SINOPHARM Pink Sheet Analysis
When running SINOPHARM GROUP's price analysis, check to measure SINOPHARM GROUP's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SINOPHARM GROUP is operating at the current time. Most of SINOPHARM GROUP's value examination focuses on studying past and present price action to predict the probability of SINOPHARM GROUP's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SINOPHARM GROUP's price. Additionally, you may evaluate how the addition of SINOPHARM GROUP to your portfolios can decrease your overall portfolio volatility.